The market expects Beam Therapeutics Inc. (BEAM) to deliver a year-over-year increase in earnings on higher revenues when it ...

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the best oversold NASDAQ stocks to buy now. On July 1, Beam Therapeutics Inc.

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company at the forefront of precision genetic medicines with a market capitalization of $1.87 billion, is navigating a critical juncture in ...

It has plenty of money, but it'll be facing plenty of competition, too. When it comes to gene-editing companies on the cutting edge, Beam Therapeutics (BEAM 0.99%) is keen to be one of the leaders.

Beam Therapeutics belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Biogen Inc. (BIIB), has gained 7.7% over the past month.

Beam Therapeutics faces slow pipeline progress and high R&D costs despite a $500M cash boost. Click here to read an analysis of BEAM stock now.

Beam Therapeutics: Cool Tech, But At A Way Inflated Price For Now Feb. 08, 2024 4:32 AM ET Beam Therapeutics Inc. (BEAM) Stock BEAM 15 Comments 1 Like Galzus Research 2.3K Follower s ...

Finally, Jones Trading upgraded shares of Beam Therapeutics from a “hold” rating to a “buy” rating and set a $34.00 price target for the company in a research report on Monday, March 10th.

Before taking the plunge into a pre-revenue gene-editing stock like Beam Therapeutics (BEAM 2.42%), which is probably years away from making any money, it's important to pause for a beat to ...

Beam Therapeutics’ project in North Carolina will be facilitated, in part, by a Job Development Investment Grant (JDIG) approved by the state’s Economic Investment Committee earlier today. The ...